<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:09:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6727161" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6727161</identifier>
        <datestamp>2019-10-25</datestamp>
        <setSpec>ajrccm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="letter">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="publisher-id">ajrccm</journal-id>
              <journal-title-group>
                <journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1073-449X</issn>
              <issn pub-type="epub">1535-4970</issn>
              <publisher>
                <publisher-name>American Thoracic Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6727161</article-id>
              <article-id pub-id-type="pmcid">PMC6727161</article-id>
              <article-id pub-id-type="pmc-uid">6727161</article-id>
              <article-id pub-id-type="pmid">30951372</article-id>
              <article-id pub-id-type="publisher-manuscript">201901-0048LE</article-id>
              <article-id pub-id-type="doi">10.1164/rccm.201901-0048LE</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Correspondence</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8837-4928</contrib-id>
                  <name>
                    <surname>Smith</surname>
                    <given-names>Jaclyn A.</given-names>
                  </name>
                  <degrees>M.B. Ch.B., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McGarvey</surname>
                    <given-names>Lorcan</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morice</surname>
                    <given-names>Alyn H.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Birring</surname>
                    <given-names>Surinder S.</given-names>
                  </name>
                  <degrees>M.B. Ch.B., M.D.</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wedzicha</surname>
                    <given-names>Jadwiga A.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fn1">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Notari</surname>
                    <given-names>Massimo</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zapata</surname>
                    <given-names>Antonio</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Segarra</surname>
                    <given-names>Rosa</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Seoane</surname>
                    <given-names>Beatriz</given-names>
                  </name>
                  <degrees>B.Sc., M.Sc.</degrees>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jarreta</surname>
                    <given-names>Diana</given-names>
                  </name>
                  <degrees>B.Chem.</degrees>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Manchester University NHS Foundation Trust<break/>Manchester, United Kingdom</aff>
                <aff id="aff2"><label><sup>2</sup></label>Queen’s University Belfast<break/>Belfast, United Kingdom</aff>
                <aff id="aff3"><label><sup>3</sup></label>Castle Hill Hospital<break/>Cottingham, United Kingdom</aff>
                <aff id="aff4"><label><sup>4</sup></label>King’s College London<break/>London, United Kingdom</aff>
                <aff id="aff5"><label><sup>5</sup></label>King’s College Hospital<break/>London, United Kingdom</aff>
                <aff id="aff6"><label><sup>6</sup></label>Imperial College London<break/>London, United Kingdom</aff>
                <aff id="aff7"><label><sup>7</sup></label>A. Menarini Farmaceutica Internazionale s.r.l.<break/>Florence, Italy</aff>
                <aff id="aff8"><label><sup>8</sup></label>Laboratorios Menarini<break/>S.A. Badalona, Spain</aff>
                <aff id="aff9"><label><sup>9</sup></label>R&amp;D Centre, AstraZeneca PLC<break/>Barcelona, Spain<break/>and</aff>
                <aff id="aff10"><label><sup>10</sup></label>University of Manchester<break/>Manchester, United Kingdom</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>*</label>Corresponding author (e-mail: <email xlink:href="jacky.smith@manchester.ac.uk">jacky.smith@manchester.ac.uk</email>).</corresp>
                <fn id="fn1">
                  <label>
                    <sup>‡</sup>
                  </label>
                  <p>J.A.W. is Editor-in-Chief of <italic>AJRCCM</italic>. Her participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub-ppub">
                <day>1</day>
                <month>9</month>
                <year>2019</year>
                <!--string-date: September 1, 2019-->
              </pub-date>
              <!--Fake epub and ppub dates generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
              <pub-date pub-type="epub">
                <day>1</day>
                <month>9</month>
                <year>2019</year>
                <!--string-date: September 1, 2019-->
              </pub-date>
              <pub-date pub-type="ppub">
                <day>1</day>
                <month>9</month>
                <year>2019</year>
                <!--string-date: September 1, 2019-->
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>9</month>
                <year>2019</year>
                <!--string-date: September 1, 2019-->
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub-ppub"/>. -->
              <volume>200</volume>
              <issue>5</issue>
              <fpage>642</fpage>
              <lpage>645</lpage>
              <permissions>
                <copyright-statement>Copyright © 2019 by the American Thoracic Society</copyright-statement>
                <copyright-year>2019</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>). For commercial usage and reprints, please contact Diane Gern (<email xlink:href="dgern@thoracic.org">dgern@thoracic.org</email>).</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="rccm.201901-0048LE.pdf"/>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <page-count count="4"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p content-type="flushleft"><italic>To the Editor</italic>:</p>
            <p content-type="flushleft">Cough and sputum production are very common and troublesome symptoms for patients with chronic obstructive pulmonary disease (COPD) (<xref rid="bib1" ref-type="bibr">1</xref>), and those symptoms are associated with lung function decline, increased exacerbation risk, and poor prognosis (<xref rid="bib2" ref-type="bibr">2</xref>–<xref rid="bib4" ref-type="bibr">4</xref>). To date, few clinical studies have investigated the efficacy of a long-acting muscarinic antagonist (LAMA) on cough (<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>). Aclidinium is a LAMA approved as a twice-daily maintenance bronchodilator treatment for patients with COPD (<xref rid="bib7" ref-type="bibr">7</xref>). This study assessed the efficacy of aclidinium on symptoms, including cough, in patients with moderate COPD. This was a phase 4, double-blind, placebo-controlled, parallel-group study (clinical trial registered with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>: NCT02375724) in 30 centers across five European countries between March 23, 2015, and November 17, 2015. Patients were randomly assigned 1:1 to receive twice-daily aclidinium 400 μg or placebo, administered via a multidose, dry powder inhaler (Genuair/Pressair, a registered trademark of the AstraZeneca group of companies, for use within the United States as Pressair and as Genuair within all other licensed territories). The study comprised a 1- to 2-week run-in period followed by an 8-week treatment period. Efficacy endpoints were measured at Week 4 and Week 8; the data over the course of 8 weeks are shown as an average of the scores measured at Week 4 and Week 8. Patients were aged at least 40 years with moderate COPD (post-bronchodilator FEV<sub>1</sub> ≥50% and &lt;80% predicted; FEV<sub>1</sub>/FVC &lt;70%). The primary endpoint was change from baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD, formerly the Exacerbations of Chronic Pulmonary Disease Tool [EXACT]-Respiratory Symptoms Scale [E-RS; <ext-link ext-link-type="uri" xlink:href="http://www.exactproinitiative.com/instrument-descriptions/">http://www.exactproinitiative.com/instrument-descriptions/</ext-link>], is owned by Evidera; permission to use this instrument may be obtained from Evidera [<ext-link ext-link-type="uri" xlink:href="http://exactpro@evidera.com">http://www.exactproinitiative.com/instrument-descriptions/exactpro@evidera.com</ext-link>]) total score over the course of 8 weeks (minimal clinically important difference [MCID], 2.0) (<xref rid="bib8" ref-type="bibr">8</xref>). Secondary efficacy endpoints were change from baseline in E-RS cough and sputum domain score over the course of 8 weeks (MCID, 0.7) (<xref rid="bib8" ref-type="bibr">8</xref>) and change from baseline in Leicester Cough Questionnaire (LCQ; MCID, 1.3) (<xref rid="bib9" ref-type="bibr">9</xref>) at Week 8. Exploratory endpoints included change from baseline in COPD Assessment Test (CAT) score (MCID, 2.0) (<xref rid="bib10" ref-type="bibr">10</xref>), cough severity visual analog scale (VAS) score, E-RS total score, and E-RS cough and sputum domain score at Week 4 and Week 8, and E-RS breathlessness (MCID, 0.1) and chest domain scores (MCID, 0.7) (<xref rid="bib8" ref-type="bibr">8</xref>) at Week 4 and Week 8 and over the course of 8 weeks. A <italic>post hoc</italic> analysis stratified patients by baseline cough severity (VAS; &gt;30 mm, more severe; ≤30 mm, less severe) to assess the effect of aclidinium on cough-related endpoints. All patients provided written informed consent; study protocols and amendments were approved by local ethics committees. The primary endpoint was analyzed using a mixed model for repeated measures.</p>
            <p>Overall, 269 patients were randomized; all had chronic bronchitis, 135 received aclidinium, and 134 received placebo. Sixty percent of patients were male, 64% were current smokers, and mean age was 62 years, with mean post-bronchodilator FEV<sub>1</sub> 64.2% predicted. In addition, patients had previously received short-acting β<sub>2</sub>-agonist (74%) and LAMA (26%). Mean baseline E-RS breathlessness, cough and sputum, and chest domain scores were 6.0, 3.7, and 2.9, respectively, and total E-RS was 12.5. Baseline CAT and LCQ scores were 19.4 and 14.5, respectively.</p>
            <p>Significant improvements in E-RS total score were observed with aclidinium versus placebo (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Aclidinium significantly improved E-RS cough and sputum domain scores versus placebo at Week 8 but not at Week 4 or over the course of 8 weeks (<xref rid="tbl1" ref-type="table">Table 1</xref>). For E-RS breathlessness domain score, aclidinium provided statistically significant improvements versus placebo at all time points (<xref rid="tbl1" ref-type="table">Table 1</xref>). Changes in LCQ total score for aclidinium versus placebo were not statistically significant at any time point (<xref rid="tbl1" ref-type="table">Table 1</xref>). Improvements in CAT and E-RS chest domain scores were numerical only (<xref rid="tbl1" ref-type="table">Table 1</xref>), as were changes in cough severity (VAS; at Week 4, −0.7; at Week 8, −1.1; over the course of 8 weeks, −0.9). In total, 264 patients were stratified by cough severity (more severe, 123 patients; less severe, 141 patients). In patients with more severe cough, significant improvements were observed in E-RS total score at Week 4, and cough and sputum domain scores at each time point (<xref rid="tbl1" ref-type="table">Table 1</xref>). Numerical differences versus placebo were observed in LCQ and E-RS breathlessness and chest domain scores, at Weeks 4 or 8, in patients with more severe cough. Statistically significant improvements were seen for patients with more severe cough versus placebo in CAT score at Weeks 4 and 8 (<xref rid="tbl1" ref-type="table">Table 1</xref>). No significant differences were observed for any outcome in patients with less severe cough.</p>
            <fig id="fig1" orientation="portrait" position="float">
              <label>Figure 1.</label>
              <caption>
                <p>Change from baseline in E-RS total score for aclidinium 400 μg versus placebo (intent-to-treat population). *<italic>P</italic> &lt; 0.05 versus placebo. Data are least squares mean ± SE. COPD = chronic obstructive pulmonary disease; E-RS = Evaluating Respiratory Symptoms in COPD (E-RS:COPD).</p>
              </caption>
              <graphic xlink:href="rccm.201901-0048LE_f1"/>
            </fig>
            <table-wrap id="tbl1" orientation="portrait" position="float">
              <label>Table 1.</label>
              <caption>
                <p>Summary of Efficacy for Aclidinium versus Placebo (Intent-to-Treat Population)</p>
              </caption>
              <!--OASIS TABLE HERE-->
              <table frame="hsides" rules="groups">
                <colgroup>
                  <col align="left"/>
                  <col align="center"/>
                  <col align="center"/>
                  <col align="center"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left"> </th>
                    <th align="center">Baseline Cough Any VAS</th>
                    <th align="center">Baseline Cough VAS &gt;30 mm (More Severe)</th>
                    <th align="center">Baseline Cough VAS <bold>≤</bold>30 mm (Less Severe)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left">E-RS total score</td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 4</td>
                    <td align="center">
                      <bold>−0.9 (0.4)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">
                      <bold>−1.3 (0.6)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−0.6 (0.6)</td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 8</td>
                    <td align="center">
                      <bold>−1.1 (0.6)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−1.2 (0.8)</td>
                    <td align="center">−1.1 (0.8)</td>
                  </tr>
                  <tr>
                    <td align="left"> Over 8 wk</td>
                    <td align="center">
                      <bold>−1.0 (0.5)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−1.2 (0.7)</td>
                    <td align="center">−0.8 (0.6)</td>
                  </tr>
                  <tr>
                    <td align="left">E-RS cough and sputum domain</td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 4</td>
                    <td align="center">−0.1 (0.1)</td>
                    <td align="center">
                      <bold>−0.3 (0.2)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">0.1 (0.2)</td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 8</td>
                    <td align="center">
                      <bold>−0.3 (0.2)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">
                      <bold>−0.5 (0.2)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−0.2 (0.2)</td>
                  </tr>
                  <tr>
                    <td align="left"> Over 8 wk</td>
                    <td align="center">−0.2 (0.1)</td>
                    <td align="center">
                      <bold>−0.4 (0.2)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−0.1 (0.2)</td>
                  </tr>
                  <tr>
                    <td align="left">LCQ</td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 4</td>
                    <td align="center">0.1 (0.3)</td>
                    <td align="center">0.6 (0.4)</td>
                    <td align="center">−0.1 (0.4)</td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 8</td>
                    <td align="center">−0.1 (0.3)</td>
                    <td align="center">0.4 (0.4)</td>
                    <td align="center">−0.4 (0.4)</td>
                  </tr>
                  <tr>
                    <td align="left">CAT total score</td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 4</td>
                    <td align="center">−0.7 (0.6)</td>
                    <td align="center">
                      <bold>−2.2 (0.8)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                      <xref ref-type="table-fn" rid="tblfn2">
                        <sup>†</sup>
                      </xref>
                    </td>
                    <td align="center">0.5 (0.8)</td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 8</td>
                    <td align="center">−0.6 (0.6)</td>
                    <td align="center">
                      <bold>−2.3 (0.9)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                      <xref ref-type="table-fn" rid="tblfn2">
                        <sup>†</sup>
                      </xref>
                    </td>
                    <td align="center">1.0 (0.9)</td>
                  </tr>
                  <tr>
                    <td align="left">E-RS breathlessness domain</td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 4</td>
                    <td align="center">
                      <bold>−0.6 (0.2)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−0.7 (0.3)</td>
                    <td align="center">−0.5 (0.3)</td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 8</td>
                    <td align="center">
                      <bold>−0.6 (0.3)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−0.5 (0.4)</td>
                    <td align="center">−0.7 (0.4)</td>
                  </tr>
                  <tr>
                    <td align="left"> Over 8 wk</td>
                    <td align="center">
                      <bold>−0.6 (0.3)</bold>
                      <xref ref-type="table-fn" rid="tblfn1">
                        <bold>*</bold>
                      </xref>
                    </td>
                    <td align="center">−0.6 (0.4)</td>
                    <td align="center">−0.6 (0.4)</td>
                  </tr>
                  <tr>
                    <td align="left">E-RS chest symptoms domain</td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                    <td align="center"> </td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 4</td>
                    <td align="center">−0.2 (0.1)</td>
                    <td align="center">−0.3 (0.2)</td>
                    <td align="center">−0.2 (0.2)</td>
                  </tr>
                  <tr>
                    <td align="left"> At Week 8</td>
                    <td align="center">−0.2 (0.2)</td>
                    <td align="center">−0.2 (0.2)</td>
                    <td align="center">−0.2 (0.2)</td>
                  </tr>
                  <tr>
                    <td align="left"> Over 8 wk</td>
                    <td align="center">−0.2 (0.1)</td>
                    <td align="center">−0.3 (0.2)</td>
                    <td align="center">−0.2 (0.2)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p><italic>Definition of abbreviations</italic>: CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; E-RS = Evaluating Respiratory Symptoms in COPD (E-RS:COPD); LCQ = Leicester Cough Questionnaire; VAS = visual analog scale.</p>
                </fn>
                <fn>
                  <p>Data are least-squares mean (SE) change from baseline for aclidinium 400 μg versus placebo. Analyzed using a mixed model for repeated measures (covariates: baseline, and age; factors: treatment group, sex, smoking status, visit, and treatment-by-visit interaction). The 30-mm VAS threshold value represented the median value of VAS baseline cough severity score and provided an almost equal split in the patient population. Bold indicates data points that are statistically significant.</p>
                </fn>
                <fn id="tblfn1">
                  <label>
                    <sup>*</sup>
                  </label>
                  <p><italic>P</italic> &lt; 0.05.</p>
                </fn>
                <fn id="tblfn2">
                  <label>
                    <sup>†</sup>
                  </label>
                  <p>Treatment difference was greater than the minimal clinically important difference (<xref rid="bib10" ref-type="bibr">10</xref>).</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>Overall, aclidinium significantly improved a range of daily COPD symptoms (including cough and sputum) versus placebo. Improvements in respiratory-specific quality-of-life measures (LCQ and CAT) did not reach statistical significance for aclidinium versus placebo in the total patient population. Baseline LCQ values in the total population suggested that the impact of symptoms on quality of life was minimal, possibly because of the number of patients with mild cough. Safety outcomes were consistent with those previously reported (<xref rid="bib11" ref-type="bibr">11</xref>).</p>
            <p><italic>Post hoc</italic> analyses showed that for patients with more severe cough, aclidinium provided greater improvements versus placebo in E-RS cough and sputum domain scores and CAT score. These patients had higher baseline CAT and E-RS total and domain scores than patients with less severe cough, and a mean LCQ of 12.7, indicating prominent cough symptoms. In contrast to the total population, when patients were stratified by cough severity, there was a numerical trend toward improvement in LCQ in patients with more severe cough versus less severe cough. This suggests baseline cough severity could be an important symptomatic marker for treatment response, and VAS score may reflect some mechanisms driving cough and sputum production in COPD, and specifically those most responsive to aclidinium treatment (<xref rid="bib12" ref-type="bibr">12</xref>).</p>
            <p>One limitation was that this study was powered for E-RS total score and E-RS cough and sputum domain, but not for CAT or LCQ scores. As the LCQ and CAT instruments are designed to capture disease effect rather than severity, these tools may not be as sensitive to symptom changes compared with those specifically designed for symptom severity, such as E-RS. In addition, only patients with moderate COPD were included; therefore, further studies in a population with more severe COPD would be beneficial.</p>
            <p>In this study, which was one of the first studies to assess the effect of a LAMA on cough outcomes in patients with COPD, aclidinium 400 μg significantly improved a range of daily symptoms, including cough, in symptomatic patients with moderate COPD compared with placebo. In addition, a subgroup of patients with more severe cough symptoms gained a distinct and early benefit from aclidinium in a number of cough-related endpoints. Therefore, routine evaluation of cough symptoms (in addition to breathlessness) may be of benefit in the treatment management of some patients with moderate COPD.</p>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Supplements</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="rccm.201901-0048LE.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="rccm.201901-0048LE_disclosures.pdf"/>
              </supplementary-material>
              <supplementary-material id="PMC_2" content-type="local-data">
                <caption>
                  <title>Author disclosures</title>
                </caption>
                <media mimetype="application" mime-subtype="pdf" xlink:href="rccm.201901-0048LE_disclosures.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <sec>
                <title>Acknowledgment</title>
                <p>The authors thank all the patients and their families and the team of investigators, research nurses, and operations staff involved in this study. Medical writing support, under the direction of the authors, was provided by Richard Knight, Ph.D., and Rebecca J. Douglas, Ph.D., from CMC Connect, a division of McCann Health Medical Communications Ltd., Macclesfield, UK in accordance with Good Publication Practice (GPP3).</p>
              </sec>
            </ack>
            <fn-group>
              <fn fn-type="supported-by">
                <p>Supported by AstraZeneca and by Menarini Group through its affiliate, Berlin Chemie.</p>
              </fn>
              <fn>
                <p>Author Contributions: All authors contributed to the conception and design of the study, data analysis/interpretation, and revision of the letter for intellectual content, and provided final approval of the letter. J.A.S. was the principal investigator of the study. All authors read and approved the final letter.</p>
              </fn>
              <fn>
                <p>Originally Published in Press as DOI: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201901-0048LE">10.1164/rccm.201901-0048LE</ext-link> on April 5, 2019</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><underline><bold><ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org/doi/suppl/10.1164/rccm.201901-0048LE/suppl_file/disclosures.pdf">Author disclosures</ext-link></bold></underline> are available with the text of this letter at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Brusselle</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Dal Negro</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Ferrer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kardos</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Levy</surname>
                      <given-names>ML</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe</article-title>
                  <source>
                    <italic>Prim Care Respir J</italic>
                  </source>
                  <year>2012</year>
                  <volume>21</volume>
                  <fpage>329</fpage>
                  <lpage>336</lpage>
                  <pub-id pub-id-type="pmid">22885563</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burgel</surname>
                      <given-names>PR</given-names>
                    </name>
                    <name>
                      <surname>Nesme-Meyer</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Chanez</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Caillaud</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Carré</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) Scientific Committee</collab>
                  <article-title>Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects</article-title>
                  <source>
                    <italic>Chest</italic>
                  </source>
                  <year>2009</year>
                  <volume>135</volume>
                  <fpage>975</fpage>
                  <lpage>982</lpage>
                  <pub-id pub-id-type="pmid">19017866</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lindberg</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sawalha</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hedman</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Larsson</surname>
                      <given-names>LG</given-names>
                    </name>
                    <name>
                      <surname>Lundbäck</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Rönmark</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Subjects with COPD and productive cough have an increased risk for exacerbations and death</article-title>
                  <source>
                    <italic>Respir Med</italic>
                  </source>
                  <year>2015</year>
                  <volume>109</volume>
                  <fpage>88</fpage>
                  <lpage>95</lpage>
                  <pub-id pub-id-type="pmid">25528948</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Putcha</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Drummond</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Connett</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Scanlon</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Tashkin</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Hansel</surname>
                      <given-names>NN</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Chronic productive cough is associated with death in smokers with early COPD</article-title>
                  <source>
                    <italic>COPD</italic>
                  </source>
                  <year>2014</year>
                  <volume>11</volume>
                  <fpage>451</fpage>
                  <lpage>458</lpage>
                  <pub-id pub-id-type="pmid">24127996</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Casaburi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Briggs</surname>
                      <given-names>DD</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Donohue</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Serby</surname>
                      <given-names>CW</given-names>
                    </name>
                    <name>
                      <surname>Menjoge</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Witek</surname>
                      <given-names>TJ</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <collab>The US Tiotropium Study Group</collab>
                  <article-title>The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial</article-title>
                  <source>
                    <italic>Chest</italic>
                  </source>
                  <year>2000</year>
                  <volume>118</volume>
                  <fpage>1294</fpage>
                  <lpage>1302</lpage>
                  <pub-id pub-id-type="pmid">11083677</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hasani</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Toms</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Agnew</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Sarno</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Dilworth</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD</article-title>
                  <source>
                    <italic>Chest</italic>
                  </source>
                  <year>2004</year>
                  <volume>125</volume>
                  <fpage>1726</fpage>
                  <lpage>1734</lpage>
                  <pub-id pub-id-type="pmid">15136383</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Bateman</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Agusti</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lamarca</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>de Miquel</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study</article-title>
                  <source>
                    <italic>Eur Respir J</italic>
                  </source>
                  <year>2012</year>
                  <volume>40</volume>
                  <fpage>830</fpage>
                  <lpage>836</lpage>
                  <pub-id pub-id-type="pmid">22441743</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leidy</surname>
                      <given-names>NK</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Monz</surname>
                      <given-names>BU</given-names>
                    </name>
                    <name>
                      <surname>Nelsen</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Goldman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>PW</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials</article-title>
                  <source>
                    <italic>Respir Res</italic>
                  </source>
                  <year>2014</year>
                  <volume>15</volume>
                  <fpage>124</fpage>
                  <pub-id pub-id-type="pmid">25287629</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9. </label>
                <mixed-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Raj</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Pavord</surname>
                      <given-names>DI</given-names>
                    </name>
                    <name>
                      <surname>Birring</surname>
                      <given-names>SS</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire?</article-title>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Chung</surname>
                      <given-names>KF</given-names>
                    </name>
                    <name>
                      <surname>Widdicombe</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <source>Pharmacology and therapeutics of cough. Handbook of experimental pharmacology. Vol. 187</source>
                  <publisher-loc>Berlin</publisher-loc>
                  <publisher-name>Springer</publisher-name>
                  <year>2009</year>
                  <fpage>311</fpage>
                  <lpage>320</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kon</surname>
                      <given-names>SSC</given-names>
                    </name>
                    <name>
                      <surname>Canavan</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Nolan</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Dickson</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Minimum clinically important difference for the COPD Assessment Test: a prospective analysis</article-title>
                  <source>
                    <italic>Lancet Respir Med</italic>
                  </source>
                  <year>2014</year>
                  <volume>2</volume>
                  <fpage>195</fpage>
                  <lpage>203</lpage>
                  <pub-id pub-id-type="pmid">24621681</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chapman</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Beck</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Alcaide</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Garcia Gil</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Overall and cardiovascular safety of aclidinium bromide in patients with COPD: a pooled analysis of six phase III, placebo-controlled, randomized studies</article-title>
                  <source>
                    <italic>Chronic Obstr Pulm Dis (Miami)</italic>
                  </source>
                  <year>2015</year>
                  <volume>3</volume>
                  <fpage>435</fpage>
                  <lpage>445</lpage>
                  <pub-id pub-id-type="pmid">28848864</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12. </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Calverley</surname>
                      <given-names>PM</given-names>
                    </name>
                  </person-group>
                  <article-title>Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment?</article-title>
                  <source>
                    <italic>Cough</italic>
                  </source>
                  <year>2013</year>
                  <volume>9</volume>
                  <fpage>17</fpage>
                  <pub-id pub-id-type="pmid">23799979</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
